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To the Editor:
Allergic disorders are common and responsible for considerable morbidity, impairment in quality of life, 
healthcare utilization and both direct and indirect healthcare costs1. For example, asthma in the U.S. affects 
an estimated of 26 million Americans, the medical expenditure is up to $4423 greater for those with 
markers of uncontrolled asthma together with a greater healthcare utilization and decreased productivity2. 
High costs are also related to patients with anaphylaxis3, urticaria4, atopic eczema/dermatitis5 and allergic 
rhinitis6.  
Studies analyzing such national trends were performed for countries such as Poland7,  UK8 and Spain9. For 
example, in the UK Gupta et al.8 analyzed trends in the prevalence, morbidity and mortality for allergic 
disorders, excluding asthma, based on hospital admission and mortality data. Studies on specific population 
subgroups showed variations in allergic disorder burden, e.g. different age groups, urban-rural division. 
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allergic rhinitis, asthma, atopic dermatitis) in metropolitan versus rural residents in Poland and found that 
the prevalence of the diseases was higher in the metropolitan areas than in rural areas, especially among 
adults. 
Although now very common, there is a relative paucity of data on U.S. national trends in allergy 
epidemiology and outcomes, we therefore undertook an analysis of trends in hospitalizations from allergic 
disorders across the U.S.
We used the National Inpatient Sample for the period 1998-2014 to analyze a sample of 130 million 
hospital discharge records of all age groups from four U.S. census regions for the following allergic 
disorders: allergic conjunctivitis, allergic rhinitis, anaphylaxis, angioedema, asthma, atopic 
eczema/dermatitis, drug allergy, food allergy, urticaria and venom allergy. ICD 9 codes were used in all 
records to classify allergic disorders. At the same time this also represents a limitation of the study since in 
some cases coding reliability might be an issue when ICD 9 codes are used. After the application of 
population weights to the sample, we had a total of 622.6 million inpatient records (3.7 million annually). 
More detailed description of the study processes and definitions is provided  as a supplement (Appendix 1 
Methods) together with a summary table of hospitalization rates from these allergic disorders by 
demographic factors (Appendix 2 Table S1). Yearly age- and sex-standardized hospitalization rates and 
trends for primary and non-primary diagnoses, defined as up to 14 diagnoses following the primary 
diagnosis, over the 17-year period were calculated using segmented generalized linear regression (Figure 
1). 
In addition, we calculated rates for: different age groups (defined as children for patients aged <15 years; 
young adults for those aged 15–44 years; and older adults for those aged 45 years and over); statistical 
regions (U.S. regions West, Midwest, Northeast and South as defined by U. S. Census Bureau); and urban-
rural division (Figure 2) adjusted with appropriate standardization rates. 
Temporal trends over the study period were estimated using segmented (piecewise) regression models, each 
segment being estimated via generalized linear model with Poisson distribution and natural logarithm link 
function, as in similar study focusing on allergic diagnoses9. Complete description of the analytic 
approaches can be found in the supplementary material (Appendix 1 Methods). Trends were shown as 
either annual percent change (APC) if no break-points were present, calculated as slopes of the regression 
function or as average annual percent change (AAPC). In both cases, we presented the estimates together 
with their 95% confidence intervals.
Increases in hospitalization rates at national levels (Figure 1A) were observed for a primary diagnosis of 
anaphylaxis (APC 2.1%, CI: 0.1,4.2) and angioedema (APC 3.3%, CI: 1.8,4.8). In contrast, decreases were 
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-1.8%, CI: -2.2,-1.4). Non-primary diagnoses showed some contrary trends, such as increases in asthma 
(AAPC 4.3%, CI: 4.1,4.5) and additional trends, such as increases in allergic rhinitis (AAPC 9.7%, CI: 
8.8,10.6) and atopic eczema/dermatitis (APC 4.2%, CI: 3.6,4.6). Allergic conjunctivitis, food allergy, and 
venom allergy showed no change (Figure 1B).
Additionally, when analyzing specific hospitalization rates (Figures 2, Appendix 3 Figure S1, and 
Appendix 4 Figure S2), we found that increases in hospitalization rates were observed for anaphylaxis, 
especially in children, for most regions, and angioedema, especially in adults and in urban hospitals. 
Decreases were observed in drug allergy, and angioedema, especially in adults, for most regions.  
Decreases in asthma hospitalization were consistent across all age groups, regions and in both urban and 
rural division. Non-primary diagnoses showed opposite trends with increases for asthma. 
Our results also showed large differences between urban and rural hospitalization rates (Figure 2) related to 
seven out of 10 allergic disorders, where either significant increase in urban hospitals (anaphylaxis, 
angioedema) or decrease in rural hospitals (asthma, atopic eczema/dermatitis, drug allergy, urticaria, venom 
allergy) were observed. 
In conclusion, recent national hospitalization data from 1998 to 2014 for allergic disorders revealed a 
complex picture with some conditions showing increased hospitalization rates across observed covariates 
(anaphylaxis and angioedema) whilst others have shown a decline (asthma, drug allergies, urticaria) or 
something in between. Of particular concern were the increased rates of anaphylaxis and angioedema in 
urban settings, where in some cases they at least doubled over the observed time period, whereas in more 
rural environments rates were stable or decreasing over the same time period. This trend analysis therefore 
provides an opportunity for policy deliberations on resource allocation for the management of allergic 
disorders in the U.S. and additional studies might clarify the implications of these trends. 
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Figure legends
Figure 1. Trends in hospitalization rates for allergic disorder diagnoses. Age- and sex-standardized 
hospitalization rates per million population of (A) primary and (B) non-primary allergic disorder diagnoses together 
with segmented regression models and the 95% confidence interval and APC or AAPC trend estimations.
Figure 2. Urban-rural trends in hospitalization rates for allergic disorder diagnoses. Age- and sex-standardized 
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respect to urban-rural division together with segmented regression models and the 95% confidence interval and APC 
or AAPC trend estimations. 
Supporting Information
Appendix 1: Methods
Appendix 2: Table S1 - Summary table of hospitalizations for allergic disorder
Appendix 3: Figure S1 - Age group trends in hospitalization rates for allergic disorder diagnoses
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